If I interpret the language correctly (I am a native English speaker, but DoH seems to write in something else) the most obvious potential for devilry is in the tariff-setting.  If it's slightly wrong, some activities will be more profitable than others.  In a PbR system, who's going to want to do the less profitable types of clinical work?

So if you have the 'wrong' type of illness, tough luck!

No idea if there's a mechanism to correct for this.  NuLab's managerial abilities in other fields suggests not.